
- NORTH AMERICA EDITIONAustraliaNorth AmericaWorld
April 05, 2022
Applied UV, Inc. (NasdaqCM: AUVI) ("Applied UV" or the "Company"), a pathogen elimination technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, announced that the Company will be hosting an investor conference call and live webcast on Thursday, April 7, 2022 at 9:00 am ET to review its financial results. Fourth quarter and Year End 2021 financial results will be available through the Investor Relations section of the company's website at https://irdirect.net/AUVI.
Conference Call/Webcast Information
Applied UV's management team will host an investor conference call and live webcast on April 7, 2022, at 9:00 am ET. Investors can access the live webcast via a link on Applied UV's web site at https://www.webcaster4.com/Webcast/Page/2626/44897. For those planning to participate on the call, please dial +1-877-545-0523 (for domestic calls), or +1-973-528-0016 (for international calls), passcode 651204. A replay of the conference call will be available online on the Applied UV web site, and a dial-in replay will be available for one week following the call at +1-877-481-4010 (for domestic calls) or +1-919-882-2331 (for international calls), replay passcode 44897.
About Applied UV
Applied UV is focused on the development and acquisition of technology that address infection control in the healthcare, hospitality, commercial and municipal markets. The Company has two wholly owned subsidiaries - SteriLumen, Inc. ("SteriLumen") and Munn Works, LLC ("Munn Works"). SteriLumen's connected platform for Data Driven Disinfection(TM) applies the power of ultraviolet light (UVC) to destroy pathogens safely, thoroughly, and automatically, addressing the challenge of healthcare-acquired infections ("HAIs"). Targeted for use in facilities that have high customer turnover such as hospitals, hotels, commercial facilities, and other public spaces, the Company's Lumicide(TM) platform uses UVC LEDs in several patented designs for infection control in and around high-traffic areas, including sinks and restrooms, killing bacteria, viruses, and other pathogens residing on hard surfaces within devices' proximity. The Company's patented in-drain disinfection device, Lumicide Drain, is the only product on the market that addresses this critical pathogen intensive location. SteriLumen's Airocide(TM) air purification devices are research backed, clinically proven, and developed for NASA with assistance from the University of Wisconsin. Airocide(TM) is listed as an FDA Class II Medical device, utilizes a proprietary photocatalytic (PCO) bioconversion technology that draws air into a reaction chamber that converts damaging molds, microorganisms, dangerous airborne pathogens, destructive VOCs, allergens, odors and biological gasses into harmless water vapor and green carbon dioxide without producing ozone or other harmful byproducts. Airocide(TM) applications include healthcare, hospitality, grocery chains, wine making facilities, commercial real estate, schools, dental offices, post-harvest, grocery, cannabis facilities and homes. For more information about Applied UV, Inc., and its subsidiaries, please visit the following websites: https://www.applieduvinc.com/; https://sterilumen.com/; https://www.airocide.com; https://kesscience.com; https://scientificairmanagement.com; www.airclean420.com, and https://munnworks.com/.
Forward-Looking Statements
The information contained herein may contain "forward-looking statements." Forward-looking statements reflect the current view about future events. When used in this press release, the words "anticipate," "believe," "estimate," "expect," "future," "intend," "plan," or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements include, but are not limited to, statements contained in this press release relating to the view of management of Applied UV concerning its business strategy, future operating results and liquidity and capital resources outlook. Forward-looking statements are based on the Company's current expectations and assumptions regarding its business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. The Company's actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Factors or events that could cause the Company's actual results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company cannot guarantee future results, levels of activity, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.
Click here to connect with Applied UV, Inc. (NasdaqCM: AUVI) to receive an Investor Presentation.
AUVI:NSD
The Conversation (0)
15 February 2022
Applied UV
Overview
Back in 2001, the National Human Activity Pattern Survey by the United States Environmental Protection Agency already stated that Americans spend around 90 percent of their time indoors. Author and Stanford University Professor Wayne Ott studied this data from 12 western countries and concluded, “The finding that emerges is that we are basically an indoor species.”
Fast forward to 2020 and the world is hit by a pandemic caused by a highly transmissible, airborne virus that reinforces the need for safe and effective sanitizing solutions to protect facilities, employees and consumers.
Indoor air quality has become an even more important issue as world economies start the recovery process. In 2021, 39 scientists reiterated the need for a "paradigm shift" and called for improvements in, "how we view and address the transmission of respiratory infections to protect against unnecessary suffering and economic losses."
In addition to this, the global air purifier market size is set to grow exponentially. It was valued at USD 9.24 billion back in 2021 and is predicted to hit around USD 22.84 billion by 2030. According to Precedence Research, the immense demand for air purification and sterilization in the US will be driven by the commercial sector.
Applied UV (NASDAQ:AUVI, AUVIP) is poised to benefit from both increased awareness and commercial demand. The company is focused on innovating new products to combat infections with products covering both airborne particles and surface sterilization and designed for a variety of industries, including healthcare, hospitality and other commercial applications.
Applied UV has two subsidiaries: SteriLumen and Munnworks. SteriLumen has three fully developed and released products that are actively combating pathogens using Photocatalytic Oxidation (PCO) and or advanced UVC sterilization technology. Munnworks, on the other hand, is a legacy company that is still active, however, it is focused on expertly designed backlit mirrors for high-end hospitality businesses.
The union of these companies has helped ensure the success of both ventures. “By joining forces, we can distribute a combined catalog of SteriLumen and Airocide® products through the Applied UV supply chain and accelerate deal flow in the hospitality, hotel, cruise ship, health care, nursing home, grocery, wine, commercial building and retail sectors,” said Applied UV Interim CEO & Director Max Munn in an interview with INN.
SteriLumen’s products do not create byproducts as HEPA filtration systems do and are independently tested to ensure they are continually effective against COVID-19 variants and other harmful pathogens. SteriLumen’s line of products attack harmful in the air, and pathogens on surfaces, plus the SteriLumen app for asset management that provides data-driven disinfection insights.
A strong management team leads Applied UV with experience in R&D, corporate finance, and various healthcare sectors, providing a stable foundation for the company to scale and grow. Interim CEO and Director Max Munn, Mike Riccio Chief Financial Officer, Interim Chief Operating Officer John Hayman III and Chairman Joel Kanter are respected in their specialties and have already demonstrated their expertise by building Applied UV to where it is today.
Company Highlights
- Applied UV is creating strategic products that cater to a direct market need, both during the pandemic and in a post-pandemic world where health and safety continue to be top priorities.
- Applied UV's patent portfolio covers 62 patents granted and pending in the United States, Canada, Europe, Australia, South America, and Asia. Applied UV continues to expand this.
- Applied UV has two subsidiaries, SteriLumen and Munnworks.
- Applied UV has acquired all of the rights to all of Scientific Air's patented, air disinfection and purification technologies.
- Applied UV received an initial order from the Tennessee Department of Correction for Scientific Air S-400 for use in its Prison and Correctional Facilities.
- Applied UV’s Airocide® is technology developed for NASA and is used by globally recognized brands. such as Del Monte, Whole Foods, Supervalu, Walmart and the Boston Red Sox’s Fenway Ballpark.
- CUBRC INC, an independent scientific not for profit testing laboratory, confirmed by a reputable Biosafety Level III Laboratory, Lumicide is proven to kill 99.9% of SARS-CoV-2 (COVID) within minutes.
- An independent study by MRIGlobal, an independent not-for-profit, contract research organization concluded that Airocide’s HD Air Purification System was proven to kill SARS-CoV-2 (COVID-19)
- Since 2015, Hungary's leading wine technology company, Cellarius, has installed Airocide® systems in more than 100 wineries in Europe.
- The US Army has installed Airocide® systems at its Aberdeen Proving Ground facility in Maryland, with the potential for future opportunities in other facilities.
Get access to more exclusive Medical Device Investing Stock profiles here
Keep reading...Show less
Science Based Photocatalytic Oxidation and UVC Products for Infection Prevention and Wellness
Latest News
Latest Press Releases
Related News
TOP STOCKS
American Battery4.030.24
Aion Therapeutic0.10-0.01
Cybin Corp2.140.00